In murine models, short-term CD-NP treatment promoted adipose tissue browning, but 12-week treatment worsened body mass, glucose tolerance, and hepatic steatosis.
OBJECTIVE: Obesity is defined as an abnormal increase in white adipose tissue (WAT) and is a major risk factor for type 2 diabetes and cardiovascular disease. Brown adipose tissue (BAT) dissipates energy and correlates with leanness. Natriuretic peptides have been shown to be beneficial for brown adipocyte differentiation and browning of WAT. METHODS: . RESULTS: In murine brown and white adipocytes, CD-NP activated cGMP production, promoted adipogenesis, and increased thermogenic markers. Consequently, mice treated for 10 days with CD-NP exhibited increased "browning" of WAT. To study CD-NP effects on diet-induced obesity (DIO), we delivered CD-NP for 12 weeks. Although CD-NP reduced inflammation in WAT, CD-NP treated DIO mice exhibited a significant increase in body mass, worsened glucose tolerance, and hepatic steatosis. Long-term CD-NP treatment resulted in an increased expression of the NP scavenging receptor (NPR-C) and decreased lipolytic activity. CONCLUSIONS: NP effects differed depending on the duration of treatment raising questions about the rational of natriuretic peptide treatment in obese patients.
Glöde et al. (Thu,) conducted a other in Obesity. CD-NP was evaluated on Adipose tissue browning, body mass, glucose tolerance, and hepatic steatosis. In murine models, short-term CD-NP treatment promoted adipose tissue browning, but 12-week treatment worsened body mass, glucose tolerance, and hepatic steatosis.